MMP7 (Matrix metallopeptidase 7)

Meta-analysis identified Krebs von den Lungen-6 (KL-6: OR = 2.21, 95% CI: 1.24 - 3.94), human Surfactant Protein D (hSP-D: OR = 1.48, 95% CI: 1.16 - 1.90), Matrix Metalloproteinase-7 (MMP-7: OR = 1.48, 95% CI: 1.13 - 1.93), and Cancer Antigen 125 (CA-125: OR = 1.19, 95% CI: 1.05 - 1.34) as risk factors for PPF development...Identifying the incidence risk and influencing factors of PPF in CTD-ILD is crucial for early identification of high-risk populations, optimizing diagnostic and therapeutic strategies, and improving prognosis. https://www.crd.york.ac.uk/prospero/, identifier CRD420251128274.

8d also induced cell apoptosis through the mitochondrial pathways, as evidenced by alterations in the expressions of pertinent proteins, including Bcl-2 and Bax. These results indicated that the novel spirotetramine derivative 8d is a potential anti-cancer candidate drug and provides a new structural basis for the development of anti-cancer drugs.

This study provides the first evidence of molecular changes in peritumour tissue to demonstrate field effect in PeSCC, characterised by downregulation of Wnt4, upregulation of c-MYC, and altered spatial colocalisation of Wnt-related proteins in cancer-adjacent skin. These findings suggest that peritumoral tissues exhibit early molecular alterations that extend beyond the morphologically defined tumour margin. Recognising these changes may have implications for understanding tumour microenvironment conditioning and for the future development of biomarkers relevant to margin assessment in penile carcinogenesis.

Thus, we revealed a protease profile (ADAM9, CTSB, MMP7, CTSC, CTSL, MMP9, and PLAU) associated with glioblastoma progression and further demonstrated that CTSL is regulated by IFN-γ in glioblastoma cells. These results establish a link between IFN-γ signaling and protease regulation in glioblastoma.

The discordance between stable MMP7 mRNA expression and declining serum MMP-7 protein levels in advanced CRC suggests complex post-transcriptional and post-translational regulation of MMP-7 during disease progression. Although this finding contrasts with much of the existing literature, it should be regarded as novel and hypothesis-generating. These results indicate that serum MMP-7 may reflect early tumor-associated processes rather than late-stage tumor burden, warranting further investigation in larger, stage-stratified and longitudinal cohorts.

The correlation between these markers offered novel insights into potential cooperative signaling pathways and presented a rational basis for the development of dual-targeted therapeutic approaches. The present study established a key foundation for future research aimed at disrupting the metastatic pathways in GC through targeted inhibition of p-EGFR and MMP7.

It was initially discovered that PAG exerts its therapeutic effects on bladder cancer by targeting multiple pathways and multiple targets. This finding will enhance our comprehension of the potential mechanism by which PAG combats bladder cancer, and it will serve as a theoretical foundation for future research endeavors.

Together, these findings provide mechanistic insights into the role of D1 in driving tumor progression and reinforce the potential of MSLN as a therapeutic biomarker. The antibody W1 emerges as a promising candidate, offering novel perspectives for developing immunotherapeutic strategies against MSLN-related cancers.

Tumors with low KIT expression exhibited enhanced immune infiltration and significant correlation with immune checkpoint genes, including PDCD1LG2 and PDCD1 (P < .05). This study identifies KIT as a key GMRG in THCA, positioning it as a novel diagnostic biomarker and a potential therapeutic evaluation marker for tumor progression.

The highest diagnostic usefulness among all the parameters was shown for MMP-7 (sensitivity (SE): 96%; specificity (SP): 94.14%; positive predictive value (PPV): 92.26%; negative predictive value (NPV): 85.46%; area under the curve (AUC): 0.9878) and MMP-10 (SE: 90.25%; SP: 80.05%; PPV: 92.15%; NPV: 88.45%; AUC: 0.9404). All parameters presented significant differences between the concentrations obtained in the CC group and the CD group, which may indicate their usefulness not only in the diagnosis of cervical cancer, but also in the possible differentiation between benign and malignant lesions.

Molecular docking showed that Cryptotanshinone possessed strong binding affinities toward EGFR ( -8.8 kcal/mol), p53 (-8.7 kcal/mol), MMP7 (-8.7 kcal/mol), and CDK8/Cyclin C (-9.8 kcal/mol), comparable to or exceeding the reference drug Erlotinib (-9.0 kcal/mol for EGFR)...Collectively, these findings highlight Cryptotanshinone from D. meyeniana as a promising natural lead for anticancer drug development, characterized by strong binding affinity, favorable pharmacokinetics, and structural stability in silico. Further in vitro and in vivo studies are warranted to confirm its therapeutic efficacy and safety.